Transitioning from Oral Invega to Long-Acting Injection
Stop the oral Invega 6 mg BID immediately and initiate paliperidone palmitate (Invega Sustenna) with 234 mg (150 mg eq.) on Day 1 followed by 156 mg (100 mg eq.) on Day 8, both administered into the deltoid muscle—no oral supplementation is required. 1, 2
Critical First Step: Verify the Current Oral Dose
Your patient is taking Invega 6 mg PO BID (12 mg/day total), which is above the typical therapeutic range. Standard oral paliperidone dosing is 3-12 mg once daily, so 12 mg/day is at the upper limit. Before switching, confirm this dose is intentional and not a prescribing error, as most patients require 6 mg once daily, not twice daily.
Standard Initiation Protocol
The FDA-approved loading regimen for paliperidone palmitate eliminates the need for oral overlap 1, 2:
- Day 1: 234 mg (150 mg eq.) deltoid injection
- Day 8: 156 mg (100 mg eq.) deltoid injection
- Day 36 and monthly thereafter: 117 mg (75 mg eq.) maintenance dose (range 39-234 mg)
Needle Selection for Loading Doses
- <90 kg: 1-inch, 23-gauge needle
- ≥90 kg: 1.5-inch, 22-gauge needle
Maintenance Injection Site Options
- Deltoid: Use weight-adjusted needle as above
- Gluteal: 1.5-inch, 22-gauge needle for all patients
Timing the Switch
Discontinue oral paliperidone the day before starting the long-acting injection 1, 2. The loading dose regimen achieves therapeutic plasma levels rapidly through the two deltoid injections one week apart, making oral supplementation unnecessary. This is a key advantage over risperidone long-acting injection, which requires 3 weeks of oral overlap 3.
Dosing Flexibility
The Day 8 dose can be given ±2 days, and monthly maintenance doses can be given ±7 days without clinically significant impact on plasma concentrations 1, 2. This flexibility helps with scheduling but should not be routinely exploited.
Maintenance Dose Considerations
Given your patient's high oral dose (12 mg/day), consider whether they will need a higher maintenance dose than the standard 117 mg monthly:
- Standard maintenance: 117 mg (75 mg eq.) monthly
- Dose range: 39-234 mg (25-150 mg eq.) monthly
- High-dose equivalent: 156-234 mg monthly may be appropriate for patients previously requiring 9-12 mg oral daily
Population pharmacokinetic modeling shows the 234 mg loading dose followed by 117 mg maintenance approximates 6 mg oral daily 1. For your patient on 12 mg/day oral, you may need to titrate to 156 mg or 234 mg monthly maintenance after the initial loading doses, based on clinical response.
Renal Function Check
Before initiating, verify creatinine clearance 1, 2:
- CrCl 50-80 mL/min (mild impairment): Reduce loading doses to 156 mg Day 1 and 117 mg Day 8; maintenance 39-156 mg monthly
- CrCl <50 mL/min: Paliperidone palmitate is not recommended
Common Pitfalls to Avoid
- Do not continue oral antipsychotics after starting the loading regimen—this increases side effect risk without benefit
- Do not use gluteal injections for the loading doses—deltoid administration is required for Days 1 and 8 to achieve rapid therapeutic levels 1, 2
- Do not assume the standard 117 mg maintenance will suffice—patients on high oral doses often require higher LAI maintenance dosing
- Do not skip the Day 8 dose—both loading doses are essential for achieving steady-state concentrations
Monitoring After Switch
Watch for extrapyramidal symptoms and akathisia, particularly in the first 4-8 weeks. If these emerge, consider dose reduction rather than adding anticholinergics long-term 4. The long-acting formulation improves adherence and reduces relapse risk compared to oral therapy, with studies showing significant delays in time-to-relapse 5 and improved patient satisfaction 6.
Future Consideration
Once stabilized on monthly injections for at least 4 months, the patient may be eligible to switch to the 3-month formulation (Invega Trinza) for even greater convenience 7, 8.